BENIGN PROSTATIC HYPERPLASIA: A POSSIBILITY TO USE TYPE 5 PHOSPHOESTERASE INHIBITORS
https://doi.org/10.21518/2079-701X-2016-19-109-113
Abstract
Prostate adenoma is a polygenic disease manifested by enlargement of the prostate gland and impaired urination. Benign prostatic hyperplasia (BPH) is quite common, many researchers say about the inevitability of this condition in men, however, prostate enlargement is not always evident clinically. The majority of patients suffering from BPH have no complaints for a long time. Depending on severity of clinical manifestations, patients may be offered dynamic follow-up, medical therapy or surgical treatment. Analysis of the existing literature has shown a possibility of effective use of Type 5 phosphodiesterase inhibitors (PDE-5) not only in the treatment of erectile dysfunction (ED) but also in the treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia. The only drug of the PDE-5 inhibitors group registered for treatment of LUTS in BPH is tadalafil use of which in equal shares is manifested by reduced severity of moderate and severe symptoms of accumulation and discharge in men with erectile dysfunction and not affected by it.
About the Authors
A. O. VASILIEV
Evdokimov Moscow State Medical and Stomatologic University of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. V. GOVOROV
Evdokimov Moscow State Medical and Stomatologic University of the Ministry of Health of Russia
Russian Federation
Russian Federation
G. R. KASYAN
Evdokimov Moscow State Medical and Stomatologic University of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
D. Y. PUSHKAR
Evdokimov Moscow State Medical and Stomatologic University of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. European Association of Urology [internet]. Available from: http://uroweb.org/wp- content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2016.pdf.
2. Zhang WH, Zhang XH. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update Asian. J Androl, 2015 Nov 27. doi: 10.4103/1008-682X.167721. [Epub ahead of print].
3. Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med, 2012 Jan, 9(1): 265-270.
4. Cantrell MA, Baye J, Vouri S.M. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy, 2013 Jun, 33(6): 639-649.
5. Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol, 2013 Mar, 63(3): 506-516.
6. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med, 2011 Oct, 8(10): 2746-2760.
7. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate, 2013 Sep, 73(13): 1391-1402.
8. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012 May, 61(5): 994-1003.
9. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol, 2007 Apr, 177(4): 1401-1407.
10. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol, 2008 Oct, 180(4): 1228-1234.
11. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol, 2009 Oct, 56(4): 727-735.
12. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med, 2012 Jan, 9(1): 271-281.
13. Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, Morisaki Y, et al. Int Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. J Urol, 2013 Feb, 20(2): 193-201.
14. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol, 2012 May, 61(5): 917-925.
15. Wang X, Wang X, Li S, Meng Z, Liu T, Zhang X. Compa rative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One, 2014 Sep 12, 9: e107593.
16. Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D. Sildenafil influences lower urinary tract symptoms. BJU Int, 2002 Dec, 90: 836-839.
17. Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int, 2014 Oct, 114: 568-575.
18. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol, 2004 Sep, 172: 1036-1041.
19. Wang X, Wang X, Liu T, He Q, Wang Y, Zhang X, et al. Systematic review and meta- analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. PLoS One, 2014 Mar, 9: e91327.
20. Govorov A, Kasyan G, Priymak D, Pushkar D, Sorsaburu S. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia Cent European. J Urol, 2014 Mar, 67: 167-177
21. Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P, et al. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK- 369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int, 2010 Sep, 106: 674-680.
Review
For citations:
VASILIEV AO, GOVOROV AV, KASYAN GR, PUSHKAR DY. BENIGN PROSTATIC HYPERPLASIA: A POSSIBILITY TO USE TYPE 5 PHOSPHOESTERASE INHIBITORS. Meditsinskiy sovet = Medical Council. 2016;(19):109-113. (In Russ.) https://doi.org/10.21518/2079-701X-2016-19-109-113
Views:
967
Email this article 